NEW YORK (GenomeWeb) – BG Medicine said today that its common stock will be delisted from Nasdaq effective at the opening of the Dec. 4, 2015 trading session.

The company was unable to maintain compliance with listing requirements for the exchange.

BG was notified on March 10, 2015 that its stock no longer qualified for listing on the exchange because it did not have a minimum bid price of at least $1 per share, and the company’s stockholder’s equity was not at least $2.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.